Physician profile
Eduard Bover
NPI 1801831763
$6,718.15
in general payments reported to CMS, 2019-2025
28 companies · $887 in 2025
The $887 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $655 · 2021: $887 · 2022: $1,178 · 2023: $1,096 · 2024: $1,111 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $89.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.02 |
| Education | $89.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $694.02 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $679.41 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Mallinckrodt Hospital Products INC. | $593.33 | 2020-2025 | Acthar, Terlivaz |
| Otsuka America Pharmaceutical, INC. | $552.99 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $521.06 | 2019-2024 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $459.11 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $410.92 | 2019-2023 | Xarelto |
| Opko Pharmaceuticals, LLC | $354.23 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $313.54 | 2021-2025 | |
| Horizon Therapeutics Plc | $312.75 | 2019-2022 | |
| Vifor Pharma, INC. | $307.22 | 2019-2024 | Veltassa, Korsuva |
| Ardelyx, INC. | $256.50 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Abbvie INC. | $238.14 | 2022-2024 | Avycaz, Teflaro, Dalvance |
| Alexion Pharmaceuticals, INC. | $227.55 | 2019-2025 | Ultomiris |
| Akebia Therapeutics INC | $157.82 | 2019-2025 | Vafseo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $127.57 | 2023-2025 | |
| Glaxosmithkline, LLC. | $116.86 | 2021-2023 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $80.03 | 2023 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $52.93 | 2023-2024 | Gattex |
| Mallinckrodt Enterprises LLC | $40.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.12 | 2024-2025 | Eliquis |
| Calliditas Therapeutics US INC. | $32.41 | 2023-2025 | Tarpeyo |
| Lexicon Pharmaceuticals, INC. | $29.18 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.92 | 2024 | Jardiance |
| Chiesi USA, INC. | $26.02 | 2021 | |
| Janssen Biotech, INC. | $25.00 | 2025 | |
| Renalytix Ai, INC. | $24.00 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Fresenius USA Manufacturing, INC. | $22.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eduard Bover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.